Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Tabula Rasa Healthcare, Tucson, AZ, USA.
Ann Pharmacother. 2022 Sep;56(9):1065-1075. doi: 10.1177/10600280211062271. Epub 2022 Jan 7.
Patients with rheumatoid arthritis (RA) experience pain from inflammation, joint destruction, and neuropathy. Antidepressants may play a role among patients with RA and depression, fibromyalgia, or neuropathy to achieve desired outcomes. This commentary evaluated evidence for medications individually and identified important variables for future research. While we await the results of well-designed studies, a trial of duloxetine or milnacipran may be considered for patients with remnant pain and RA remission. Research is needed to evaluate the efficacy and safety of serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants in patients with RA and associated comorbid conditions.
类风湿关节炎(RA)患者会因炎症、关节破坏和神经病变而感到疼痛。抗抑郁药可能在 RA 合并抑郁、纤维肌痛或神经病变的患者中发挥作用,以达到预期的治疗效果。本述评评估了这些药物的个体疗效证据,并确定了未来研究的重要变量。在我们等待精心设计的研究结果的同时,对于仍有疼痛且处于 RA 缓解期的患者,可以考虑使用度洛西汀或米那普仑。需要开展研究来评估 5-羟色胺-去甲肾上腺素再摄取抑制剂和三环类抗抑郁药在合并相关疾病的 RA 患者中的疗效和安全性。